Canceled: The DiGAs re.flex and Kaia COPD were unable to prove their effectiveness during the trial period. Trial period extended: Novego, Selfapys online course for chronic pain, ProHerz and NeuroNation have been given more time to prove their effectiveness. Effectiveness successfully proven: The following DiGA apps were able to prove their effectiveness during the trial period and switched to permanent approval status: Endo-App, Vitadio and priori. Risk classes: 65% of DiGA apps were classified according to MDD when they were first approved. Following partial recertification, 38% of DiGAs are now still MDD-approved and benefit from the extension of the transition period. Availability: 56 of 64 DiGAs
LINK